ECSP014055A - Activadores de glucoquinasa que contienen hidantoina - Google Patents

Activadores de glucoquinasa que contienen hidantoina

Info

Publication number
ECSP014055A
ECSP014055A EC2001004055A ECSP014055A ECSP014055A EC SP014055 A ECSP014055 A EC SP014055A EC 2001004055 A EC2001004055 A EC 2001004055A EC SP014055 A ECSP014055 A EC SP014055A EC SP014055 A ECSP014055 A EC SP014055A
Authority
EC
Ecuador
Prior art keywords
glucoquinase
activators containing
containing hydantoin
hydantoin
activators
Prior art date
Application number
EC2001004055A
Other languages
English (en)
Inventor
Robert Alan Goodnow
Kang Le
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP014055A publication Critical patent/ECSP014055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de hidantoína que son activos como activadores de la glucoquinasa para aumentar la secreción de insulina, lo cual los hace útiles para el tratamiento de la diabetes tipo II.
EC2001004055A 2000-05-03 2001-05-03 Activadores de glucoquinasa que contienen hidantoina ECSP014055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20149800P 2000-05-03 2000-05-03

Publications (1)

Publication Number Publication Date
ECSP014055A true ECSP014055A (es) 2002-01-25

Family

ID=22746054

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004055A ECSP014055A (es) 2000-05-03 2001-05-03 Activadores de glucoquinasa que contienen hidantoina

Country Status (20)

Country Link
US (2) US6583288B2 (es)
EP (1) EP1280801B1 (es)
JP (1) JP3842131B2 (es)
KR (1) KR100505312B1 (es)
CN (1) CN1209361C (es)
AR (1) AR034253A1 (es)
AT (1) ATE304011T1 (es)
AU (2) AU5227001A (es)
BR (1) BR0110492A (es)
CA (1) CA2407428C (es)
DE (1) DE60113247T2 (es)
DK (1) DK1280801T3 (es)
EC (1) ECSP014055A (es)
ES (1) ES2248309T3 (es)
MX (1) MXPA02010746A (es)
PE (1) PE20011313A1 (es)
PT (1) PT1280801E (es)
UY (1) UY26689A1 (es)
WO (1) WO2001083478A2 (es)
ZA (1) ZA200208370B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5227001A (en) * 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
MXPA05003559A (es) 2002-10-03 2005-06-03 Novartis Ag (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
PT1723128E (pt) * 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
BRPI0514515A (pt) * 2004-08-17 2008-06-10 Hoffmann La Roche hidantoìnas substituìdas
JP2008512456A (ja) 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド 三環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
ATE464305T1 (de) * 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
KR20080024211A (ko) 2005-07-08 2008-03-17 노보 노르디스크 에이/에스 디시클로알킬 우레아 글루코키나제 활성제
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
DK1951658T3 (da) 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
FR2894962B1 (fr) * 2005-12-20 2008-03-14 Pharmamens Sarl Hydantoines a action insulinotropique
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8148390B2 (en) * 2007-03-12 2012-04-03 Merck, Sharp & Dohme, Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
CN101778839A (zh) 2007-08-16 2010-07-14 霍夫曼-拉罗奇有限公司 取代的乙内酰脲
WO2009080523A1 (en) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as mek kinase inhibitors
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
HRP20150842T1 (hr) 2008-04-28 2015-09-11 Kyorin Pharmaceutical Co., Ltd. Derivati ciklopentilakrilamida
EA018988B1 (ru) 2008-05-16 2013-12-30 Такеда Калифорния, Инк. Активаторы глюкокиназы
WO2010150280A1 (en) 2009-06-22 2010-12-29 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
MY156175A (en) 2009-07-31 2016-01-15 Cadila Healthcare Ltd Substituted benzamide derivatives as glucokinase (gk) activators
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
ES2671881B1 (es) * 2016-11-11 2019-03-25 Consejo Superior Investigacion Procedimiento de obtencion de polimeros con grupos isocianato
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN116194442A (zh) 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
AU5227001A (en) * 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators

Also Published As

Publication number Publication date
ZA200208370B (en) 2004-01-26
WO2001083478A3 (en) 2002-05-16
PE20011313A1 (es) 2001-12-28
BR0110492A (pt) 2003-04-08
AU2001252270B2 (en) 2005-12-15
WO2001083478A2 (en) 2001-11-08
KR20020093120A (ko) 2002-12-12
ES2248309T3 (es) 2006-03-16
EP1280801A2 (en) 2003-02-05
US6784298B2 (en) 2004-08-31
US6583288B2 (en) 2003-06-24
US20030225286A1 (en) 2003-12-04
CA2407428A1 (en) 2001-11-08
DE60113247D1 (de) 2005-10-13
CA2407428C (en) 2010-02-02
CN1209361C (zh) 2005-07-06
KR100505312B1 (ko) 2005-08-04
MXPA02010746A (es) 2003-03-10
JP3842131B2 (ja) 2006-11-08
ATE304011T1 (de) 2005-09-15
AU5227001A (en) 2001-11-12
PT1280801E (pt) 2005-11-30
AR034253A1 (es) 2004-02-18
JP2003531905A (ja) 2003-10-28
DK1280801T3 (da) 2006-01-23
UY26689A1 (es) 2001-11-30
CN1427838A (zh) 2003-07-02
US20010056191A1 (en) 2001-12-27
EP1280801B1 (en) 2005-09-07
DE60113247T2 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
UY26689A1 (es) Activadores de glucocinasa que contienen hidantoina
UY26694A1 (es) Activadores de fenil glucocinasa para - arilo o hetero sustituidos
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
GT200300096A (es) Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
SV2009003235A (es) Triazoles biciclicos como moduladores de la proteina cinasa ref. x-18476m
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
PA8493701A1 (es) Compuestos para tratar la obesidad
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
GT200600429A (es) Compuestos organicos
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos